Medical Devices: What Those Paying Are Saying
Executive Summary
The Affordable Care Act is shifting the economic risks of care from the payors to the providers, and medtech companies will be forced to find new sales and distribution channels, new ways of defining clinical and economic benefit, and new offerings wrapped around devices to enhance both their clinical and economic value. At the IN3 meeting in October 2013, executives from both the payor and provider communities discussed how medtech companies should respond to these new dynamics.
You may also be interested in...
Medtronic Signals More To Come On Its Pivot To Hospital Services
The company’s leadership team is “determined to transform Medtronic from being a primarily device provider today into the premier global medical technology solutions partner of tomorrow,” CEO Omar Ishrak said.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.